Getting industrial

Second Genome Inc. hired a new president and CEO who is returning to the drug discovery game after spending much of the last 20 years coaxing products from industrial biotech platforms. The company and its investors expect Glenn Nedwin to do the same for the microbiome company.

Second Genome studies bacteria and their interactions with host systems to identify new targets on either the host or the bacteria. It hits those targets with traditional large or small molecule therapeutics...